Edgar P Simard1, Ruth M Pfeiffer, Eric A Engels. 1. Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS 7076, Rockville, MD 20892, USA.
Abstract
BACKGROUND: Persons living with AIDS today remain at elevated cancer risk. Highly active antiretroviral therapy (HAART), widely available since 1996, prolongs life, but immune function is not fully restored. We conducted this study to assess long-term cancer risk among persons with AIDS relative to the general population and the impact of HAART on cancer incidence. METHODS: Records of 263 254 adults and adolescents with AIDS (1980-2004) from 15 US regions were matched to cancer registries to capture incident cancers during years 3 through 5 and 6 through 10 after AIDS onset. Standardized incidence ratios (SIRs) were used to assess risks relative to the general population. Rate ratios (RRs) were used to compare cancer incidence before and after 1996 to assess the impact of availability of HAART. RESULTS: Risk was elevated for the 2 major AIDS-defining cancers: Kaposi sarcoma (SIRs, 5321 and 1347 in years 3-5 and 6-10, respectively) and non-Hodgkin lymphoma (SIRs, 32 and 15). Incidence of both malignancies declined in the HAART era (1996-2006). Risk was elevated for all non-AIDS-defining cancers combined (SIRs, 1.7 and 1.6 in years 3-5 and 6-10, respectively) and for the following specific non-AIDS-defining cancers: Hodgkin lymphoma and cancers of the oral cavity and/or pharynx, tongue, anus, liver, larynx, lung and/or bronchus, and penis. Anal cancer incidence increased between 1990-1995 and 1996-2006 (RR, 2.9; 95% confidence interval [CI], 2.1-4.0), as did that of Hodgkin lymphoma (RR, 2.0; 95% CI, 1.3-2.9). CONCLUSION: Among people who survived for several years or more after an AIDS diagnosis, we observed high risks of AIDS-defining cancers and increasing incidence of anal cancer and Hodgkin lymphoma.
BACKGROUND:Persons living with AIDS today remain at elevated cancer risk. Highly active antiretroviral therapy (HAART), widely available since 1996, prolongs life, but immune function is not fully restored. We conducted this study to assess long-term cancer risk among persons with AIDS relative to the general population and the impact of HAART on cancer incidence. METHODS: Records of 263 254 adults and adolescents with AIDS (1980-2004) from 15 US regions were matched to cancer registries to capture incident cancers during years 3 through 5 and 6 through 10 after AIDS onset. Standardized incidence ratios (SIRs) were used to assess risks relative to the general population. Rate ratios (RRs) were used to compare cancer incidence before and after 1996 to assess the impact of availability of HAART. RESULTS: Risk was elevated for the 2 major AIDS-defining cancers: Kaposi sarcoma (SIRs, 5321 and 1347 in years 3-5 and 6-10, respectively) and non-Hodgkin lymphoma (SIRs, 32 and 15). Incidence of both malignancies declined in the HAART era (1996-2006). Risk was elevated for all non-AIDS-defining cancers combined (SIRs, 1.7 and 1.6 in years 3-5 and 6-10, respectively) and for the following specific non-AIDS-defining cancers: Hodgkin lymphoma and cancers of the oral cavity and/or pharynx, tongue, anus, liver, larynx, lung and/or bronchus, and penis. Anal cancer incidence increased between 1990-1995 and 1996-2006 (RR, 2.9; 95% confidence interval [CI], 2.1-4.0), as did that of Hodgkin lymphoma (RR, 2.0; 95% CI, 1.3-2.9). CONCLUSION: Among people who survived for several years or more after an AIDS diagnosis, we observed high risks of AIDS-defining cancers and increasing incidence of anal cancer and Hodgkin lymphoma.
Authors: Nancy Crum-Cianflone; Katherine Huppler Hullsiek; Vincent Marconi; Amy Weintrob; Anuradha Ganesan; R Vincent Barthel; Susan Fraser; Brian K Agan; Scott Wegner Journal: AIDS Date: 2009-01-02 Impact factor: 4.177
Authors: Kenneth A Katz; Christina A Clarke; Kyle T Bernstein; Mitchell H Katz; Jeffrey D Klausner Journal: Ann Intern Med Date: 2009-02-17 Impact factor: 25.391
Authors: O Kirk; C Pedersen; A Cozzi-Lepri; F Antunes; V Miller; J M Gatell; C Katlama; A Lazzarin; P Skinhøj; S E Barton Journal: Blood Date: 2001-12-01 Impact factor: 22.113
Authors: W E Cunningham; L E Markson; R M Andersen; S H Crystal; J A Fleishman; C Golin; A Gifford; H H Liu; T T Nakazono; S Morton; S A Bozzette; M F Shapiro; N S Wenger Journal: J Acquir Immune Defic Syndr Date: 2000-10-01 Impact factor: 3.731
Authors: Douglas D Richman; Sally C Morton; Terri Wrin; Nicholas Hellmann; Sandra Berry; Martin F Shapiro; Samuel A Bozzette Journal: AIDS Date: 2004-07-02 Impact factor: 4.177
Authors: Gary M Clifford; Martin Rickenbach; Mauro Lise; Luigino Dal Maso; Manuel Battegay; Julia Bohlius; Emmanuelle Boffi El Amari; Urs Karrer; Gernot Jundt; Andrea Bordoni; Silvia Ess; Silvia Franceschi Journal: Blood Date: 2009-03-31 Impact factor: 22.113
Authors: L Stewart Massad; Xianhong Xie; Teresa Darragh; Howard Minkoff; Alexandra M Levine; D Heather Watts; Rodney L Wright; Gypsyamber D'Souza; Christine Colie; Howard D Strickler Journal: Obstet Gynecol Date: 2011-10 Impact factor: 7.661
Authors: Anna E Coghill; Meredith S Shiels; Randi K Rycroft; Glenn Copeland; Jack L Finch; Anne M Hakenewerth; Karen S Pawlish; Eric A Engels Journal: AIDS Date: 2016-01-02 Impact factor: 4.177
Authors: Hilary A Robbins; Ruth M Pfeiffer; Meredith S Shiels; Jianmin Li; H Irene Hall; Eric A Engels Journal: J Natl Cancer Inst Date: 2015-02-06 Impact factor: 13.506
Authors: Angel M Mayor; Eduardo J Santiago-Rodriguez; Eddy Rios-Olivares; Guillermo Tortolero-Luna; Robert F Hunter-Mellado Journal: Int J Cancer Res Date: 2016-03-15
Authors: George Kurdgelashvili; Graça M Dores; Samer A Srour; Anil K Chaturvedi; Mark M Huycke; Susan S Devesa Journal: Cancer Date: 2013-04-11 Impact factor: 6.860